Hyperbaric oxygen treatment impacts oxidative stress markers in patients with necrotizing soft-tissue infection

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Hyperbaric oxygen treatment impacts oxidative stress markers in patients with necrotizing soft-tissue infection. / Hedetoft, Morten; Jensen, Peter Østrup; Moser, Claus; Vinkel, Julie; Hyldegaard, Ole.

In: Journal of Investigative Medicine, Vol. 69, No. 7, 2021, p. 1330-1338.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Hedetoft, M, Jensen, PØ, Moser, C, Vinkel, J & Hyldegaard, O 2021, 'Hyperbaric oxygen treatment impacts oxidative stress markers in patients with necrotizing soft-tissue infection', Journal of Investigative Medicine, vol. 69, no. 7, pp. 1330-1338. https://doi.org/10.1136/jim-2021-001837

APA

Hedetoft, M., Jensen, P. Ø., Moser, C., Vinkel, J., & Hyldegaard, O. (2021). Hyperbaric oxygen treatment impacts oxidative stress markers in patients with necrotizing soft-tissue infection. Journal of Investigative Medicine, 69(7), 1330-1338. https://doi.org/10.1136/jim-2021-001837

Vancouver

Hedetoft M, Jensen PØ, Moser C, Vinkel J, Hyldegaard O. Hyperbaric oxygen treatment impacts oxidative stress markers in patients with necrotizing soft-tissue infection. Journal of Investigative Medicine. 2021;69(7):1330-1338. https://doi.org/10.1136/jim-2021-001837

Author

Hedetoft, Morten ; Jensen, Peter Østrup ; Moser, Claus ; Vinkel, Julie ; Hyldegaard, Ole. / Hyperbaric oxygen treatment impacts oxidative stress markers in patients with necrotizing soft-tissue infection. In: Journal of Investigative Medicine. 2021 ; Vol. 69, No. 7. pp. 1330-1338.

Bibtex

@article{8febe160b7e242e8b23fdf462c069476,
title = "Hyperbaric oxygen treatment impacts oxidative stress markers in patients with necrotizing soft-tissue infection",
abstract = "Necrotizing soft-tissue infection (NSTI) is a rare, severe, and fast-progressing bacterial infection associated with a high risk of developing sepsis or septic shock. Increasing evidence indicates that oxidative stress is crucial in the development and progression of sepsis, but its role in NSTI specifically has not been investigated. Some patients with NSTI receive hyperbaric oxygen (HBO2) treatment as the restoration of oxidative stress balance is considered an important mechanism of action, which HBO2 facilitates. However, a gap in knowledge exists regarding the effect of HBO2 treatment on oxidative stress in patients with NSTI. In the present observational study, we aimed to investigate HBO2 treatment effects on known markers of oxidative stress in patients with NSTI. We measured plasma myeloperoxidase (MPO), superoxide dismutase (SOD), heme oxygenase-1 (HO-1) and nitrite+nitrate in 80 patients with NSTI immediately before and after their first HBO2 treatment, and on the following day. We found that HBO2 treatment was associated with a significant increase in MPO and SOD by a median of 3.4 and 8.8 ng/mL, respectively. Moreover, we observed an HBO2 treatment-associated increase in HO-1 in patients presenting with septic shock (n=39) by a median of 301.3 pg/mL. All markers were significantly higher in patients presenting with septic shock compared to patients without shock, and all markers correlated with disease severity. High baseline SOD was associated with 90-day mortality. In conclusion, HBO2 treatment was associated with an increase in MPO and SOD in patients with NSTI, and oxidative stress was more pronounced in patients with septic shock. ",
keywords = "hyperbaric oxygenation, oxidants, sepsis",
author = "Morten Hedetoft and Jensen, {Peter {\O}strup} and Claus Moser and Julie Vinkel and Ole Hyldegaard",
note = "Publisher Copyright: {\textcopyright} American Federation for Medical Research 2021. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ.",
year = "2021",
doi = "10.1136/jim-2021-001837",
language = "English",
volume = "69",
pages = "1330--1338",
journal = "Journal of Investigative Medicine",
issn = "1081-5589",
publisher = "Lippincott Williams & Wilkins",
number = "7",

}

RIS

TY - JOUR

T1 - Hyperbaric oxygen treatment impacts oxidative stress markers in patients with necrotizing soft-tissue infection

AU - Hedetoft, Morten

AU - Jensen, Peter Østrup

AU - Moser, Claus

AU - Vinkel, Julie

AU - Hyldegaard, Ole

N1 - Publisher Copyright: © American Federation for Medical Research 2021. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ.

PY - 2021

Y1 - 2021

N2 - Necrotizing soft-tissue infection (NSTI) is a rare, severe, and fast-progressing bacterial infection associated with a high risk of developing sepsis or septic shock. Increasing evidence indicates that oxidative stress is crucial in the development and progression of sepsis, but its role in NSTI specifically has not been investigated. Some patients with NSTI receive hyperbaric oxygen (HBO2) treatment as the restoration of oxidative stress balance is considered an important mechanism of action, which HBO2 facilitates. However, a gap in knowledge exists regarding the effect of HBO2 treatment on oxidative stress in patients with NSTI. In the present observational study, we aimed to investigate HBO2 treatment effects on known markers of oxidative stress in patients with NSTI. We measured plasma myeloperoxidase (MPO), superoxide dismutase (SOD), heme oxygenase-1 (HO-1) and nitrite+nitrate in 80 patients with NSTI immediately before and after their first HBO2 treatment, and on the following day. We found that HBO2 treatment was associated with a significant increase in MPO and SOD by a median of 3.4 and 8.8 ng/mL, respectively. Moreover, we observed an HBO2 treatment-associated increase in HO-1 in patients presenting with septic shock (n=39) by a median of 301.3 pg/mL. All markers were significantly higher in patients presenting with septic shock compared to patients without shock, and all markers correlated with disease severity. High baseline SOD was associated with 90-day mortality. In conclusion, HBO2 treatment was associated with an increase in MPO and SOD in patients with NSTI, and oxidative stress was more pronounced in patients with septic shock.

AB - Necrotizing soft-tissue infection (NSTI) is a rare, severe, and fast-progressing bacterial infection associated with a high risk of developing sepsis or septic shock. Increasing evidence indicates that oxidative stress is crucial in the development and progression of sepsis, but its role in NSTI specifically has not been investigated. Some patients with NSTI receive hyperbaric oxygen (HBO2) treatment as the restoration of oxidative stress balance is considered an important mechanism of action, which HBO2 facilitates. However, a gap in knowledge exists regarding the effect of HBO2 treatment on oxidative stress in patients with NSTI. In the present observational study, we aimed to investigate HBO2 treatment effects on known markers of oxidative stress in patients with NSTI. We measured plasma myeloperoxidase (MPO), superoxide dismutase (SOD), heme oxygenase-1 (HO-1) and nitrite+nitrate in 80 patients with NSTI immediately before and after their first HBO2 treatment, and on the following day. We found that HBO2 treatment was associated with a significant increase in MPO and SOD by a median of 3.4 and 8.8 ng/mL, respectively. Moreover, we observed an HBO2 treatment-associated increase in HO-1 in patients presenting with septic shock (n=39) by a median of 301.3 pg/mL. All markers were significantly higher in patients presenting with septic shock compared to patients without shock, and all markers correlated with disease severity. High baseline SOD was associated with 90-day mortality. In conclusion, HBO2 treatment was associated with an increase in MPO and SOD in patients with NSTI, and oxidative stress was more pronounced in patients with septic shock.

KW - hyperbaric oxygenation

KW - oxidants

KW - sepsis

U2 - 10.1136/jim-2021-001837

DO - 10.1136/jim-2021-001837

M3 - Journal article

C2 - 34006573

AN - SCOPUS:85106147344

VL - 69

SP - 1330

EP - 1338

JO - Journal of Investigative Medicine

JF - Journal of Investigative Medicine

SN - 1081-5589

IS - 7

ER -

ID: 270626911